Free Trial

Sami Corwin Analyst Performance

Analyst at William Blair

Sami Corwin is a stock analyst at William Blair, covering 4 publicly traded companies across a range of sectors. Over the past year, Sami Corwin has issued 4 stock ratings, including buy and hold recommendations. While full access to Sami Corwin's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Sami Corwin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
50.00% 2 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy50.0%2 ratings
Hold50.0%2 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Sami Corwin at William Blair, the majority (50.0%) have been Buy recommendations, followed by 50.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
4 companies

Sami Corwin, an analyst at William Blair, currently covers 4 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

Sami Corwin of William Blair specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
100.0%

Sami Corwin's Ratings History at William Blair

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
8/20/2025Initiated Coverage$3.30Outperform
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6/20/2025Reiterated Rating$20.77Market Perform
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5/28/2025Initiated Coverage$35.08$65.00Outperform
Nkarta, Inc. stock logo
NKTX
Nkarta
5/15/2025Reiterated Rating$1.87Market Perform